drugset
drugset / Trial / NCT06128044

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06128044 ↗

Phase 1 Terminated 12 enrolled Caribou Biosciences, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of treatment for AML .

Timeline

Start
2024-02-08
Primary completion
2025-05-30
Completion
2025-05-30

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision - Pipeline Reprioritization”

Drugs

EvaluationDrugModalityDoseRoute
Subject CB-012 Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

acute myeloid leukemia